Hims & Hers Health reported Q3 2026 revenue of $890.3 million, slightly missing analyst consensus by $2.5 million but meeting midpoint guidance. The company strategically reduced marketing spend to 28% of revenue, down from 39% the previous year, in preparation for its upcoming partnership with Eli Lilly on GLP-1 weight loss medicines and international brand consolidation. Gross margins dipped to 57% due to the Eucalyptus business integration and are expected to stay lower with branded GLP-1 deals. Despite the minor revenue miss, the stock trades at a low valuation, presenting a strong long-term growth opportunity with major catalysts expected in Q4.
As of Nov 11, 2026 03:51 WIB, Hims & Hers Health (HIMS) shares are trading at USD 18.93 on Pluang, down 17.50% in the last day. Despite the sharp drop, the stock maintains a market cap of $5.35 billion and sees a balanced order activity with 59% of trades buying and 41% selling. The typical hold time for HIMS on Pluang is 24 days, indicating moderate investor interest.
Hims & Hers reported a surprise Q3 loss and cut its full-year profit outlook, causing its stock to drop 18%. Despite 48.6% revenue growth, the company missed revenue estimates and faced margin pressure due to lower-margin weight-loss products and int...
Hims & Hers stock dropped 25.67% in a week following its deal with Eli Lilly to expand access to weight-loss drugs, despite Lilly's modest share gains. The decline reflects challenges from Hims' shift to branded GLP-1 drugs, including a drop in gross...
Hims & Hers reported a 49% increase in Q3 revenue to $890.4 million, driven by a 321% surge in international sales, partly due to the acquisition of Eucalyptus. However, gross margins fell sharply from 73.8% to 57.2%, and the company lost 100,000 sub...
Anthropic, the AI company behind Claude, is set to begin trading next week after ending its 15-day waiting period post-S-1 filing. The company aims to raise $80B-$100B with a valuation between $1.25T and $1.75T, potentially making it the largest IPO ...
Hims & Hers Health lowered its 2026 profit forecast for the third time this year after reporting a surprise $33 million quarterly loss. Revenue grew 49% to $890.4 million, but gross margin dropped due to a shift toward lower-margin weight-loss drugs....
